Company Focus

Galderma

Latest Galderma News

New Galderma Phase IIIb data reinforce Relfydess benefits
Pharmaceutical
Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of relabotulinumtoxinA (now trade named Relfydess) to treat frown lines (glabellar lines).   31 January 2025


Insights

Company Spotlight

Latest News & Features of interest to Galderma

Latest In Brief for Galderma

Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.   15 October 2024

Latest Dermatology Ones To Watch News

Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria candidate AK006 following disappointing Phase I trial results. Also, Merck & Co said it was halting the Winrevair HYPERIO trial in pulmonary arterial hypertension (PAH) early due to positive findings. On the M&A front, Lantheus announced it is expanding its radiopharmaceutial portfolio with the acquisition of Evergreen Theragnostics, and its lead product Octevy, for around $1 billion. Also of note, the US Food Administration (FDA) at last approved Vertex Pharmaceutical’s non-opioid pain drug Journavx (suzetrigine).   2 February 2025

More in M&A >


Dermatology Ones to Watch Companies

Reset all filters
Refine Search